Analysts expect Alliqua BioMedical, Inc. (NASDAQ:ALQA) to post ($0.12) earnings per share (EPS) for the current quarter, Zacks reports. Two analysts have issued estimates for Alliqua BioMedical’s earnings. The lowest EPS estimate is ($0.16) and the highest is ($0.07). Alliqua BioMedical posted earnings per share of ($0.30) during the same quarter last year, which suggests a positive year over year growth rate of 60%. The business is expected to report its next earnings results on Friday, November 3rd.

On average, analysts expect that Alliqua BioMedical will report full-year earnings of ($0.49) per share for the current fiscal year, with EPS estimates ranging from ($0.72) to ($0.25). For the next fiscal year, analysts forecast that the company will report earnings of ($0.23) per share, with EPS estimates ranging from ($0.35) to ($0.10). Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that that provide coverage for Alliqua BioMedical.

Alliqua BioMedical (NASDAQ:ALQA) last posted its quarterly earnings results on Thursday, August 10th. The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.05. Alliqua BioMedical had a negative return on equity of 107.24% and a negative net margin of 185.30%. The business had revenue of $5.52 million during the quarter, compared to analysts’ expectations of $5.01 million. During the same quarter last year, the company posted ($0.22) earnings per share. Alliqua BioMedical’s quarterly revenue was up 23.5% on a year-over-year basis.

Several research analysts have recently weighed in on the stock. Zacks Investment Research raised shares of Alliqua BioMedical from a “hold” rating to a “buy” rating and set a $0.50 price objective for the company in a report on Tuesday, August 15th. HC Wainwright set a $2.00 price objective on shares of Alliqua BioMedical and gave the company a “buy” rating in a report on Thursday, May 11th. Finally, ValuEngine cut shares of Alliqua BioMedical from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $1.31.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC boosted its position in Alliqua BioMedical by 23.2% in the fourth quarter. Renaissance Technologies LLC now owns 410,400 shares of the company’s stock valued at $242,000 after buying an additional 77,400 shares during the last quarter. KCG Holdings Inc. boosted its position in Alliqua BioMedical by 777.7% in the first quarter. KCG Holdings Inc. now owns 525,077 shares of the company’s stock valued at $265,000 after buying an additional 465,256 shares during the last quarter. Sabby Management LLC boosted its position in Alliqua BioMedical by 93.7% in the first quarter. Sabby Management LLC now owns 2,131,050 shares of the company’s stock valued at $1,076,000 after buying an additional 1,030,652 shares during the last quarter. Finally, Perceptive Advisors LLC boosted its position in Alliqua BioMedical by 120.3% in the first quarter. Perceptive Advisors LLC now owns 4,233,951 shares of the company’s stock valued at $2,136,000 after buying an additional 2,312,000 shares during the last quarter. 21.68% of the stock is owned by hedge funds and other institutional investors.

Alliqua BioMedical (NASDAQ:ALQA) traded down 5.13% during trading on Wednesday, reaching $0.37. The company had a trading volume of 1,488,744 shares. The company has a 50-day moving average price of $0.34 and a 200 day moving average price of $0.43. Alliqua BioMedical has a one year low of $0.23 and a one year high of $1.04. The company’s market capitalization is $18.54 million.

TRADEMARK VIOLATION WARNING: This article was originally published by Watch List News and is the property of of Watch List News. If you are viewing this article on another publication, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this article can be read at https://www.watchlistnews.com/0-12-eps-expected-for-alliqua-biomedical-inc-alqa-this-quarter/1532424.html.

Alliqua BioMedical Company Profile

Alliqua BioMedical, Inc is a provider of advanced wound care solutions. The Company’s businesses include advanced wound care and contract manufacturing. The Company operates through its subsidiaries, such as AquaMed Technologies, Inc and Choice Therapeutics, Inc The Company is engaged in developing a suite of advanced wound care solutions that will enable surgeons, clinicians and wound care practitioners to address the challenges in chronic and acute wounds.

Get a free copy of the Zacks research report on Alliqua BioMedical (ALQA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Alliqua BioMedical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alliqua BioMedical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.